Lonza to double ADC capacity to address Visp challenge

Lonza to double ADC capacity

Lonza plans to double ADC capacity at its facility in Visp, Switzerland by 2014 in a move that it says could create new jobs.

The Swiss supplier announced the investment today, explaining that while antibody drug conjugates (ADCs) are one of the fastest growing segments for the industry manufacturing them is a challenge that involves handling both biologics and toxic small molecule drugs.

Stefan Stoffel, head of Lonza’s chemical manufacturing unit, said: “We have witnessed significant growth in the ADC market in the past 24 months and this investment is necessary to continue to support the growing product demands from our customers.”

The move – which will see Lonza invest some CHF14m (€11.5m) - is one of a number of recent contract manufacturing industry investments in ADC manufacturing capability.

In July last year French contract manufacturing organisation (CMO) Novasep said it would spend €3m ($m) to add ADC capacity at its facility in Le Mans, also citing customer demand.

More recently, Fujifilm Diosynth Biotechnologies entered the ADC sector through a partnership with Indian CMO Piramal Healthcare.

Visp challenge

Lonza has been producing ADCs at the Visp facility since the mid-2000s when it established a laboratory-scale manufacturing suite and pilot plant.

The decision to double capacity at Visp fits with Lonza’s plan to make the facility more cost competitive by conducting more high value, high margin development and manufacturing work. These efforts have already seen Lonza undertake a number of ADC development and clinical-scale production projects at the Visp plant.

Lonza's suggestion the ADC investment "potential to bring new job opportunities across all functions in Visp" contrasts with the job cuts the firm carried out at the facility late last year.

Related News

ADC invests in production tech

ADC Bio open to antibody drug conjugate collaborations and CMO takovers

Lonza rejigs structure

Lonza rejigs ops and says more changes are to follow

Catalent enters ADC market

Catalent Gets ADC Tech and Enters Fast-Growing Niche Market

Fujifilm's Cell Banking Facilitates "Larger Slice" of Biologics Pie

Fujifilm's Cell Banking Facilitates "Larger Slice" of Biologics Pie

Lonza Manufacturing Issues Cause Increlex Shortages in US, EU

Lonza Closes Ireland Site as US Manufacturing Issues Cause Increlex Shortage

Goodwin

Demand Across Biopharma Drives Goodwin and Coldstream ADC Partnership

ADC Bio Expands Lab Services in Response to Demand

ADC Bio Expands Lab Services in Response to Demand

Lonza and Teva Abandon Biosimilars JV

Lonza and Teva Abandon Biosimilars JV; Lonza Plans Site 'Consolidations'

Lonza to Focus on CMO and Cell Line Biz

Lonza to Focus on Biologics CMO and Cell Line Biz Post Teva Biosimilars JV

Lonza Licenses Cell Line Tech to Sorrento

Lonza Licenses Expression Tech to Second Firm in Two Weeks

Eli Lilly could pay Immunogen up to $200m for use of its ADC tech

Eli Lilly Licenses $200m ADC Tech from Immunogen

Fujifilm opts for Xcellerex tech at UK plant

Fujifilm Diosynth Biotechnologies opts for Xcellerex tech at new UK plant

Competition not a concern says Carbogen Amcis CEO

Carbogen Amcis CEO: Competition in ADC sector not a concern

Another day, another ADC investment: SAFC adds ADC capacity

Another day, another ADC investment: SAFC adds commercial-scale capacity

ADCs a big opportunity for Big Pharma say experts

Big Pharma business opportunities driving ADC boom say experts

Lonza says Pharma and restructuiring efforts are on track

Lonza says Pharma business and restructuring efforts are on track

Lonza cites ADC investment and GS Xceed gains in Asia as Q3 drivers

Lonza cites ADC investment and GS Xceed gains in Asia as Q3 drivers

Swiss CDMO Lonza selected for biologics development and manufacturing

Index Ventures selects Lonza for exclusive 5-year biologics contract

Talking ADCs with SAFC, Piramal and Catalent at CPhI Frankfurt

'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI

MacroGenics extends license of Polytherics' Thiobridge ADC tech

MacroGenics extends license of Polytherics' Thiobridge ADC tech

Lonza adding single-use systems at its clinical ADC facility in Visp, Switzerland

ADC pipelines drive single-use expansion at Lonza's clinical facility

CMOs dominate the manufacturing of ADCs though there are only a limited number that can develop linkers and cytotoxins.

Vast majority of ADC manufacturing outsourced, report finds

Manufacturing deals for DSM, Lonza, ARk and AMRI

News from Lonza, DSM, Ark and AMRI

Lonza tweaks E.coli system; 'no' to takeover speculation

Lonza tweaks E.coli expression system; denies takeover rumours

Lonza to make enzyme-replacement therapy

Lonza to produce Phase 2b enzyme-replacement therapy

Lonza, IP, Asia, gene expression

Lonza stresses importance of IP protection in Asia

Lonza says SSB accord will boost capacity utilisation

Lonza teams with Sartorius on media to boost capacity utilisation

Lonza to make preclinical trial supplies of an antibody-drug conjugate (ADC) at its facility in Visp, Switzerland

Lonza to make antibody conjugates for preclinical trials

Lonza contracted by Celladon for trial supplies

Lonza wins second high-tech trial supply contract in a week

Lonza signs deal to make antibody-drug conjugates for Intellect Neurosciences.

Lonza to make preclinical antibody conjugates for Intellect Neurosciences

Cobra expands board

Former Lonza biologics CSO joins Cobra board

Related Products

See more related products